<DOC>
	<DOCNO>NCT02708186</DOCNO>
	<brief_summary>This study seek evaluate safety efficacy Nelotanserin treatment Rapid Eye Movement ( REM ) Sleep Behavior Disorder ( RBD ) subject dementia Lewy body ( DLB ) Parkinson 's disease dementia ( PDD ) .</brief_summary>
	<brief_title>Study Evaluating Nelotanserin Treatment REM Sleep Behavior Disorder Subjects With Dementia ( DLB PDD )</brief_title>
	<detailed_description>This double-blind , randomize , placebo-controlled , parallel-arm study subject DLB PDD RBD . Subjects meet randomization criterion randomize 1:1 receive Nelotanserin placebo 28 day double-blind period .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<mesh_term>REM Sleep Behavior Disorder</mesh_term>
	<criteria>Adult subject least 50 year age , diagnosis DLB PDD RBD base Diagnostic Statistical Manual Mental Disorders Fifth Edition ( DSM5 ) diagnostic criterion Presence frequent REM sleep behavior episode Mini Mental State Examination score â‰¥ 18 Subjects current diagnosis significant psychotic disorder include , limited , schizophrenia bipolar disorder Subjects ' RBD symptom secondary well account another medical condition , psychiatric disorder , substance abuse Subjects current serious and/or unstable cardiovascular , respiratory , thyroid , gastrointestinal , renal , hematologic medical disorder</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Dementia Lewy body</keyword>
	<keyword>Lewy body</keyword>
	<keyword>REM sleep behavior disorder</keyword>
	<keyword>Parkinson 's disease dementia</keyword>
</DOC>